Maia Wealth LLC Buys 565 Shares of Eli Lilly and Company (NYSE:LLY)

Key Points

• Maia Wealth LLC increased its stake in Eli Lilly by 22.3% by acquiring an additional 565 shares, bringing their total holdings to 3,093 shares valued at approximately $2.33 million.
• Institutional investors own 82.53% of Eli Lilly's stock, with notable increases in holdings from firms such as PNC Financial Services Group and GAMMA Investing LLC.
• Analysts have mixed ratings on Eli Lilly, with an average rating of "Moderate Buy" and an average price target of $984.41, reflecting varying opinions on the stock's future performance.

Maia Wealth LLC boosted its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 22.3% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,093 shares of the company's stock after acquiring an additional 565 shares during the quarter. Maia Wealth LLC's holdings in Eli Lilly and Company were worth $2,334,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the stock. PNC Financial Services Group Inc. lifted its position in Eli Lilly and Company by 97.5% in the 1st quarter. PNC Financial Services Group Inc. now owns 101,305,650 shares of the company's stock valued at $83,669,349,000 after acquiring an additional 50,002,551 shares in the last quarter. Vanguard Group Inc. lifted its position in Eli Lilly and Company by 6.7% in the 1st quarter. Vanguard Group Inc. now owns 79,224,392 shares of the company's stock valued at $65,432,218,000 after acquiring an additional 4,975,395 shares in the last quarter. GAMMA Investing LLC lifted its position in Eli Lilly and Company by 103,831.6% in the 1st quarter. GAMMA Investing LLC now owns 14,866,380 shares of the company's stock valued at $12,278,292,000 after acquiring an additional 14,852,076 shares in the last quarter. Capital Research Global Investors lifted its position in Eli Lilly and Company by 16.1% in the 4th quarter. Capital Research Global Investors now owns 10,757,511 shares of the company's stock valued at $8,304,811,000 after acquiring an additional 1,493,673 shares in the last quarter. Finally, Northern Trust Corp lifted its position in Eli Lilly and Company by 14.6% in the 4th quarter. Northern Trust Corp now owns 9,448,219 shares of the company's stock valued at $7,294,025,000 after acquiring an additional 1,204,337 shares in the last quarter. 82.53% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts recently commented on LLY shares. Guggenheim boosted their price objective on shares of Eli Lilly and Company from $936.00 to $942.00 and gave the company a "buy" rating in a research report on Friday, July 11th. Leerink Partners reissued a "market perform" rating and set a $715.00 price target on shares of Eli Lilly and Company in a research report on Thursday. Cantor Fitzgerald assumed coverage on shares of Eli Lilly and Company in a research report on Tuesday, April 22nd. They set an "overweight" rating and a $975.00 price target on the stock. UBS Group cut their price target on shares of Eli Lilly and Company from $1,050.00 to $895.00 and set a "buy" rating on the stock in a research report on Friday. Finally, HSBC cut shares of Eli Lilly and Company from a "buy" rating to a "reduce" rating and cut their price target for the stock from $1,150.00 to $700.00 in a research report on Monday, April 28th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and sixteen have issued a buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $984.41.

Eli Lilly and Company Stock Performance

NYSE LLY opened at $625.15 on Monday. The stock has a market cap of $591.68 billion, a PE ratio of 40.86, a P/E/G ratio of 0.87 and a beta of 0.44. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The firm has a 50-day moving average of $774.10 and a 200-day moving average of $799.34. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $972.53.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, beating the consensus estimate of $5.59 by $0.72. The firm had revenue of $15.56 billion for the quarter, compared to analysts' expectations of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The business's revenue was up 37.6% on a year-over-year basis. During the same period in the prior year, the firm earned $3.92 EPS. On average, sell-side analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th will be issued a $1.50 dividend. This represents a $6.00 annualized dividend and a yield of 1.0%. The ex-dividend date of this dividend is Friday, August 15th. Eli Lilly and Company's dividend payout ratio is currently 48.82%.

Insiders Place Their Bets

In related news, Director Jamere Jackson purchased 200 shares of the stock in a transaction on Friday, August 8th. The shares were purchased at an average cost of $639.56 per share, with a total value of $127,912.00. Following the acquisition, the director directly owned 9,402 shares in the company, valued at $6,013,143.12. The trade was a 2.17% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. 0.14% of the stock is currently owned by corporate insiders.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.